nAMD patients successfully switch from aflibercept to biosimilar ranibizumab
A recent study showed that patients with neovascular age-related macular degeneration (nAMD) who transition from aflibercept to biosimilar ranibizumab maintained visual acuity and macular anatomy despite changes in fluid management. The study,1 published …